Skip to main content

Valbenazine Tosylate

Brand names: Ingrezza

Oral

At a glance

Medicare prescriptions, 2024
192,441
Medicare drug cost
$1.45B
Average cost per prescription
$7,536
Clinicians who prescribed it
8,287

Where it is prescribed

Loading map…

List the prescribers in any state, county, city or ZIP code →

What it is used for

INGREZZA and INGREZZA SPRINKLE are indicated for the treatment of adults with: - tardive dyskinesia. - chorea associated with Huntington’s disease.

From the FDA-approved prescribing information (label dated April 2026). Full labels on DailyMed (opens in a new tab)

Boxed warning

WARNING: DEPRESSION AND SUICIDAL IDEATION AND BEHAVIOR IN PATIENTS WITH HUNTINGTON’S DISEASE VMAT2 inhibitors, including INGREZZA and INGREZZA SPRINKLE, can increase the risk of depression and suicidal thoughts and behavior in patients with Huntington’s disease. Anyone considering the use of INGREZZA or INGREZZA SPRINKLE must balance the risks of depression and suicidal ideation and behavior with the clinical need for treatment of chorea. Closely monitor patients for the emergence or worsening of depression, suicidal ideation, or unusual changes in behavior. Inform patients, their caregivers, and families of the risk of depression and suicidal ideation and behavior and instruct them to report behaviors of concern promptly to the treating physician. Particular caution should be exercised in treating patients with a history of depression or prior suicide attempts or ideation, which are…

The FDA’s strongest warning on a label. It doesn’t mean the drug is unsafe for most people; talk to your doctor or pharmacist before stopping or changing any medicine.

Who prescribes it

All prescribers, by place, name or specialty →

Share of Medicare prescriptions written by each specialty. Select one to list its prescribers.

Trend, 2019–2024

Medicare prescriptions rose 197% from 2019 to 2024.

Medicare Part D prescriptions per year, all prescribers
  • 201986,146
  • 2020111,991
  • 2021130,034
  • 2022172,518
  • 2023225,616
  • 2024255,987

From CMS’s yearly state and national Part D summaries, which count every prescriber, including those CMS leaves out of its per-clinician data (fewer than 11 prescriptions). That is why these totals are higher than the count at the top of this page. Prescriptions include refills.

What it looks like

Pills from 1 maker on file. The same medicine can look different depending on who made it, so check the imprint (the letters and numbers on the pill) with your pharmacist if a refill looks different.

Neurocrine Biosciences, Inc.

StrengthLooks likeImprint
40 mgpurple capsule, 18 mmVBZ 40
40 mgwhite capsule, 22 mmVBZ 40
60 mgpurple capsule, 18 mmVBZ 60
60 mgwhite capsule, 22 mmVBZ 60
80 mgpurple capsule, 19 mmVBZ 80
80 mgwhite capsule, 22 mmVBZ 80

Source: DailyMed (U.S. National Library of Medicine), from each maker’s FDA drug listing. A few makers are shown, not every one. Never take a pill you can’t identify; ask a pharmacist.

Industry payments about this drug

Drug makers reported $17.3M in payments to clinicians that named this drug in 2025 (meals, speaking, consulting and similar).

  • Neurocrine Biosciences, Inc. $17.3M

See all companies →

Source: CMS Open Payments, general payments (not research), program year 2025. A payment is not evidence of wrongdoing. Payments by doctor

Recalls and shortages

Not on the FDA drug shortage list.

No FDA-reported recalls since 2020.

Sources: CMS Medicare Part D Prescribers by Provider and Drug (2024; prescriptions include refills, and CMS hides counts under 11 per prescriber); U.S. Food and Drug Administration, openFDA (drug labels, NDC directory, enforcement reports, drug shortages); CMS Open Payments 2025; ClinicalTrials.gov. General information only, not medical advice; not yet reviewed by our medical reviewer.